Artículo
Castro, C.N.; Barcala Tabarrozi, A.E.; Noguerol, M.A.; Liberman, A.C.; Dewey, R.A.; Arzt, E.; Morelli, A.E.; Perone, M.J. "Disease-modifying immunotherapy for the management of autoimmune diabetes" (2010) NeuroImmunoModulation. 17(3):173-176
Estamos trabajando para incorporar este artículo al repositorio
Consulte la política de Acceso Abierto del editor
Abstract:
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that destroys the insulin-secreting β-cells of the pancreas. It is now possible to predict those candidates that will progress to T1D before the full onset of the disease. Prevention of uncontrollable autoimmunity against β-cells in therapies for T1D is mandatory to preserve the β-cell mass. Therefore, immunomodulatory strategies directed to inhibiting the activity of self-reactive T cell clones as well as induction of regulatory T cells would be beneficial for prevention of T1D or recurrence of β-cell autoimmunity against islet cell allografts. © 2010 S. Karger AG, Basel.
Registro:
| Documento: | Artículo |
| Título: | Disease-modifying immunotherapy for the management of autoimmune diabetes |
| Autor: | Castro, C.N.; Barcala Tabarrozi, A.E.; Noguerol, M.A.; Liberman, A.C.; Dewey, R.A.; Arzt, E.; Morelli, A.E.; Perone, M.J. |
| Filiación: | Laboratorio de Fisiología y Biología Molecular (LFBM), IFIBYNE-CONICET, Universidad de Buenos Aires, Pabellón II-2o piso, Buenos Aires 1428, Argentina Laboratorio de Terapia Génica y Células Madre, Instituto de Investigaciones Biotecnológicas-Instituto Tecnológico de Chascomús, CONICET-UNSAM, Chascomús, Argentina Department of Surgery and Immunology, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, United States |
| Palabras clave: | Dendritic cells; Immunoregulation; Type 1 diabetes; autoimmune disease; autoimmunity; cell activity; cell clone; cell cloning; cell destruction; cell disruption; conference paper; dendritic cell; disease course; human; immunomodulation; immunoregulation; immunotherapy; inner cell mass; insulin dependent diabetes mellitus; lymphocyte preservation; nonhuman; pancreas islet beta cell; priority journal; regulatory T lymphocyte; T lymphocyte; Animals; Antirheumatic Agents; Autoimmunity; Dendritic Cells; Diabetes Mellitus, Type 1; Disease Models, Animal; Humans; Immunomodulation; Immunotherapy; Insulin-Secreting Cells; T-Lymphocytes, Helper-Inducer |
| Año: | 2010 |
| Volumen: | 17 |
| Número: | 3 |
| Página de inicio: | 173 |
| Página de fin: | 176 |
| DOI: | http://dx.doi.org/10.1159/000258716 |
| Título revista: | NeuroImmunoModulation |
| Título revista abreviado: | NeuroImmunomodulation |
| ISSN: | 10217401 |
| CODEN: | NROIE |
| CAS: | Antirheumatic Agents |
| Registro: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10217401_v17_n3_p173_Castro |
Referencias:
- Atkinson, M.A., Eisenbarth, G.S., Type1 diabetes: New perspectives on disease pathogenesis and treatment (2001) Lancet, 358, pp. 221-229
- Bach, J.F., The effect of infections on susceptibility to autoimmune and allergic diseases (2002) N Engl J Med, 347, pp. 911-920
- Willcox, A., Richardson, S.J., Bone, A.J., Foulis, A.K., Morgan, N.G., Analysis of islet inflammation in human type 1 diabetes (2008) Clin Exp Immunol, 155, pp. 173-181
- Christianson, S.W., Shultz, L.D., Leiter, E.H., Adoptive transfer of diabetes into immunodeficient NOD-SCID/SCID mice: Relative contributions of CD4 + and CD8 + T-cells from diabetic versus prediabetic NOD. NONThy- 1a donors (1993) Diabetes, 42, pp. 44-55
- Chang, C.L.T., Chang, S.L., Lee, Y.M., Chiang, Y.M., Chuang, D.Y., Kuo, H.K., Yang, W.C., Cytopiloyne, a polyacetylenic glucoside, prevents type 1 diabetes in nonobese diabetic mice (2007) J Immunol, 178, pp. 6984-6993
- Perone, M.J., Bertera, S., Shufesky, W.J., Divito, S.J., Montecalvo, A., Mathers, A.R., Larregina, A.T., Morelli, A.E., Suppression of autoimmune diabetes by soluble galectin-1 (2009) J Immunol, 182, pp. 2641-2653
- Jain, R., Tartar, D.M., Gregg, R.K., Divekar, R.D., Bell, J.J., Lee, H.-H., Yu, P., Zaghouani, H., Innocuous IFNγ induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production (2008) J Exp Med, 205, pp. 207-218
- Nurieva, R., Yang, X.O., Chung, Y., Dong, C., Cutting Edge: In vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts (2009) J Immunol, 182, pp. 2565-2568
- Emamaullee, J.A., Davis, J., Merani, S., Toso, C., Elliott, J.F., Thiesen, A., Shapiro, A.M.J., Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice (2009) Diabetes, 58, pp. 1302-1311
- Herold, K.C., Gitelman, S.E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Bluestone, J.A., A single course of anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes (2005) Diabetes, 54, pp. 1763-1769
- Perone, M.J., Larregina, A.T., Shufesky, W.J., Papworth, G.D., Sullivan, M.L.G., Zahorchak, A.F., Stolz, D.B., Morelli, A.E., Transgenic galectin-1 induces maturation of dendritic cells that elicit contrasting responses on naïve and activated T cells (2006) J Immunol, 176, pp. 7207-7220
- Perone, M.J., Bertera, S., Shufesky, W.J., Zahorchak, A., Piganelli, J., Baum, L.G., Trucco, M., Morelli, A.E., Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice (2006) J Immunol, 177, pp. 5278-5289
- MacHen, J., Harnaha, J., Lakomy, R., Styche, A., Trucco, M., Giannoukakis, N., Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells (2004) J Immunol, 173, pp. 4331-4341
Citas:
---------- APA ----------
Castro, C.N., Barcala Tabarrozi, A.E., Noguerol, M.A., Liberman, A.C., Dewey, R.A., Arzt, E., Morelli, A.E.,..., Perone, M.J. (2010) . Disease-modifying immunotherapy for the management of autoimmune diabetes. NeuroImmunoModulation, 17(3), 173-176.http://dx.doi.org/10.1159/000258716
---------- CHICAGO ----------
Castro, C.N., Barcala Tabarrozi, A.E., Noguerol, M.A., Liberman, A.C., Dewey, R.A., Arzt, E., et al. "Disease-modifying immunotherapy for the management of autoimmune diabetes" . NeuroImmunoModulation 17, no. 3 (2010) : 173-176.http://dx.doi.org/10.1159/000258716
---------- MLA ----------
Castro, C.N., Barcala Tabarrozi, A.E., Noguerol, M.A., Liberman, A.C., Dewey, R.A., Arzt, E., et al. "Disease-modifying immunotherapy for the management of autoimmune diabetes" . NeuroImmunoModulation, vol. 17, no. 3, 2010, pp. 173-176.http://dx.doi.org/10.1159/000258716
---------- VANCOUVER ----------
Castro, C.N., Barcala Tabarrozi, A.E., Noguerol, M.A., Liberman, A.C., Dewey, R.A., Arzt, E., et al. Disease-modifying immunotherapy for the management of autoimmune diabetes. NeuroImmunomodulation. 2010;17(3):173-176.http://dx.doi.org/10.1159/000258716
